ArticleInternational journal of MS care2025
Ocrelizumab Wearing-Off Phenomenon: Prevalence, Predictors, and Outcomes After Intervention.
Article in International journal of MS care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies have suggested a wearing-off phenomenon characterized by subjective worsening of symptoms prior to subsequent infusions in more than half of people with multiple sclerosis (MS) treated with ocrelizumab. This study assesses the prevalence, characteristics, predictive factors, and impacts of different interventions on wearing off in a large cohort of people with MS receiving ocrelizumab. Methods: Clinical records of people with MS receiving ocrelizumab were reviewed to collect demographic variables, clinical characteristics, comorbidities, presence of wearing off and its specific symptoms, and responses after interventions to wearing off. Logistic regression modeling was used to assess predictors of wearing off. Results: Wearing off was observed in 24.8% of 528 people with MS receiving ocrelizumab, most often characterized by worsening residual focal symptoms (79.4%) and fatigue (67.2%). Risk factors for wearing off included obesity (OR, 1.93; Conclusions: Wearing off was observed in nearly a quarter of people with MS receiving ocrelizumab. Clinicians should be aware of predictive factors for wearing off with ocrelizumab and that interventions were generally effective at mitigating this phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.